{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:48:32Z","timestamp":1781063312236,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.vaccine.2015.03.001","type":"journal-article","created":{"date-parts":[[2015,3,22]],"date-time":"2015-03-22T17:19:28Z","timestamp":1427044768000},"page":"2500-2510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial"],"prefix":"10.1016","volume":"33","author":[{"given":"Stan L.","family":"Block","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Szenborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Jackowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.03.001_bib0230","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.03.001_bib0235","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0240","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0245","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3201\/eid1206.051297","article-title":"Social behavior and meningococcal carriage in British teenagers","volume":"12","author":"MacLennan","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0250","first-page":"205","article-title":"Meningococcal disease control in countries of the African meningitis belt, 2013","volume":"89","author":"World Health Organization (WHO)","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.03.001_bib0255","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0265","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial","volume":"383","author":"Daugla","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0270","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1473-3099(12)70168-8","article-title":"Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data","volume":"12","author":"Novak","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0275","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14760584.5.4.445","article-title":"Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135","volume":"5","author":"Keyserling","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0280","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/IDR.S12716","article-title":"Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease","volume":"4","author":"Broker","year":"2011","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0285","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix)","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0290","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0295","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2009.10.104","article-title":"Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0300","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0305","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0310","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0315","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0320","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0325","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0330","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0335","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0340","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CmenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0345","series-title":"Presented at the 19th International Pathogenic Neisseria Conference (IPNC)","first-page":"269","article-title":"Use of the meningococcal antigen typing system (MATS) to assess the Australian meningococcal strain coverage with a multicomponent serogroup B vaccine","author":"Nissen","year":"2012"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0350","series-title":"Presented at the 19th International Pathogenic Neisseria Conference (IPNC)","first-page":"270","article-title":"Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States","author":"Kim","year":"2012"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0355","series-title":"Presented at the 19th International Pathogenic Neisseria Conference (IPNC)","first-page":"272","article-title":"MATS based coverage prediction for the 4CMenB vaccine on Neisseria meningitidis B (MenB) Brazilian invasive strains","author":"Lemos","year":"2012"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0360","series-title":"5th Vaccine & International Society for Vaccines Annual Global Congress","article-title":"Estimated coverage of Canadian meningococcal B isolates by a meningococcal serogroup B vaccine","author":"Bettinger","year":"2011"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0365","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0370","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0375","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0380","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0385","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0390","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Centers for Diseases Control and Prevention","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0395","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cid\/cit243","article-title":"Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States","volume":"57","author":"Mandal","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0400","series-title":"Princeton University meningococcal disease outbreak","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0405","series-title":"University of California, Santa Barbara meningococcal disease outbreak","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0410","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/CVI.05028-11","article-title":"Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis","volume":"18","author":"Mak","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0415","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/00224065.1980.11980968","article-title":"Simultaneous optimization of several response variables","volume":"12","author":"Derringer","year":"1980","journal-title":"J Qual Technol"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0420","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1586\/14760584.2014.880341","article-title":"Neisseria meningitidis B vaccines: recent advances and possible immunization policies","volume":"13","author":"Gasparini","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0425","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1086\/322578","article-title":"Evaluating the immune response to combination vaccines","volume":"33","author":"Ball","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0430","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernink","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0435","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0440","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.03.001_bib0445","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.001_bib0450","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.4161\/hv.29218","article-title":"A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)","volume":"10","author":"Esposito","year":"2014","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15002741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15002741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T17:38:38Z","timestamp":1651599518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15002741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":45,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0264410X15002741"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}